Camenzind Roland S, Wieser Karl, Fessel Gion, Meyer Dominik C, Snedeker Jess G
Department of Orthopedics, Balgrist University Hospital, Forchstrasse 340, 8008, Zurich, Switzerland.
Institute for Biomechanics, ETH Zurich, Zurich, Switzerland.
Clin Orthop Relat Res. 2016 Aug;474(8):1778-85. doi: 10.1007/s11999-016-4838-8. Epub 2016 Apr 18.
The suture-tendon interface is often the weakest link in tendon to bone repair of massive rotator cuff tears. Genipin is a low-toxicity collagen crosslinker derived from the gardenia fruit that has been shown to augment collagen tissue strength and mechanically arrest tendon-tear progression.
QUESTION/PURPOSE: The purpose of the current study was to evaluate whether genipin crosslinking can sufficiently augment the suture-tendon interface to improve suture pullout strength using simple single-loop sutures and the modified Mason-Allen technique. The study also aimed to assess whether time of genipin treatment is a relevant factor in efficacy.
In an ex vivo (cadaveric) sheep rotator cuff tendon model, a total of 142 suture pullout tests were performed on 32 infraspinatus tendons. Each tendon was prepared with three single-loop stitches. Two groups were pretreated by incubation in genipin solution for either 4 hours or 24 hours. Two corresponding control groups were incubated in phosphate buffered saline for the same periods. The same test protocol was applied to tendons using modified Mason-Allen technique stitch patterns. Each suture was loaded to failure on a universal materials testing machine. Suture pullout force, stiffness, and work to failure were calculated from force-displacement data, and then compared among the groups.
Median single-loop pullout force on tendons incubated for 24 hours in genipin yielded an approximately 30% increase in maximum pullout force for single-loop stitches with a median of 73 N (range, 56-114 N) compared with 56 N (range, 40-69 N; difference of medians = 17 N; p = 0.028), with corresponding increases in the required work to failure but not stiffness. Genipin treatment for 4 hours showed no added benefit for suture-pullout behavior (46 N, [range, 35-95 N] versus 45 N, [range, 28-63 N]; difference of medians, 1 N; p = 1). No tested genipin crosslinking conditions indicated benefit for tendons grasped using the modified Mason-Allen technique after 4 hours (162 N, [range, 143-193 N] versus 140 N, [range, 129-151 N]; difference of medians, 22 N; p = 0.114) or after 24 hours of crosslinking (172 N, [range, 42-183 N] versus 164 N [range, 151-180 N]; difference of medians, 8 N; p = 0.886).
Exogenous collagen crosslinking in genipin can markedly improve resistance to pullout at the tendon-suture interface for simple stitch patterns while the modified Mason-Allen stitch showed no benefit in an ex vivo animal model.
Tendon strength augmentation by genipin pretreatment offers the potential to improve suture retention properties. Future studies are warranted for the development of clinically viable intraoperative delivery strategies and in vivo testing for safety and efficacy.
在巨大肩袖撕裂的肌腱至骨修复中,缝线 - 肌腱界面往往是最薄弱的环节。京尼平是一种从栀子果实中提取的低毒性胶原蛋白交联剂,已被证明可增强胶原组织强度并机械性阻止肌腱撕裂进展。
问题/目的:本研究的目的是评估使用简单单环缝线和改良梅森 - 艾伦技术时,京尼平交联是否能充分增强缝线 - 肌腱界面以提高缝线拔出强度。该研究还旨在评估京尼平处理时间是否是影响疗效的相关因素。
在体外(尸体)绵羊肩袖肌腱模型中,对32条冈下肌腱进行了总共142次缝线拔出试验。每条肌腱用三个单环缝线进行准备。两组分别在京尼平溶液中孵育4小时或24小时进行预处理。两个相应的对照组在相同时间段内于磷酸盐缓冲盐水中孵育。使用改良梅森 - 艾伦技术缝线模式对肌腱应用相同的测试方案。每条缝线在万能材料试验机上加载至失效。根据力 - 位移数据计算缝线拔出力、刚度和失效功,然后在各组之间进行比较。
在京尼平中孵育24小时的肌腱上,单环拔出力中位数显示,单环缝线的最大拔出力增加了约30%,中位数为73 N(范围56 - 114 N),而对照组为56 N(范围40 - 69 N;中位数差异 = 17 N;p = 0.028),失效所需功相应增加,但刚度未增加。京尼平处理4小时对缝线拔出行为无额外益处(46 N,[范围35 - 95 N]对45 N,[范围28 - 63 N];中位数差异,1 N;p = 1)。在4小时(162 N,[范围143 - 193 N]对140 N,[范围129 - 151 N];中位数差异,22 N;p = 0.114)或交联24小时后(172 N,[范围42 - 183 N]对164 N [范围151 - 180 N];中位数差异,8 N;p = 0.886),没有测试的京尼平交联条件表明对使用改良梅森 - 艾伦技术抓取的肌腱有益。
在体外动物模型中,京尼平中的外源性胶原蛋白交联可显著提高简单缝线模式下肌腱 - 缝线界面的抗拔出能力,而改良梅森 - 艾伦缝线未显示出益处。
京尼平预处理增强肌腱强度为改善缝线保留性能提供了潜力。未来有必要开展临床可行的术中给药策略及体内安全性和有效性测试的研究。